Research Summary

Telemedicine Follow-up Improves Outcomes in Advanced COPD After Exacerbation

Miranda Manier, BA

Key Highlights

  • In a randomized controlled trial of 74 patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbation, telemedicine follow-up over 3 months significantly improved COPD Assessment Test (CAT) scores compared with face-to-face care.
  • Correct inhaler technique was achieved by 91.4% of patients in the telemedicine group versus 65.7% in the control group.
  • Inhaler adherence was higher in the telemedicine group (70.6% vs 55.9%), though the difference was not statistically significant.
  • Patients expressed high satisfaction with telemedicine, suggesting it is a feasible and effective alternative for post-exacerbation COPD follow-up.

A prospective, randomized controlled trial evaluated the safety and effectiveness of telemedicine compared with traditional face-to-face follow-up in patients with advanced chronic obstructive pulmonary disease (COPD) following hospitalization for exacerbation. Results showed that telemedicine improved symptom burden and inhaler technique, with high patient satisfaction, suggesting it may serve as a viable alternative to standard care.

COPD is a leading cause of morbidity and mortality worldwide, and patients with advanced disease are especially vulnerable to recurrent exacerbations, hospitalizations, and declining quality of life. The COVID-19 pandemic accelerated interest in telemedicine as a strategy for chronic disease management, but evidence for its utility in severe COPD, particularly in the post-exacerbation setting, has been limited. This study investigated whether telemedicine follow-up could improve patient-reported outcomes and adherence compared with standard outpatient follow-up.

Seventy-four patients with GOLD stage 3–4 COPD and at least one prior hospitalization were enrolled after admission for an exacerbation. Participants were randomized to telemedicine follow-up (n = 37) or standard outpatient clinic follow-up (n = 37). The telemedicine group received scheduled video visits at day 10, 1 month, and 3 months, with additional visits as needed. The control group followed routine outpatient care schedules. Outcomes included COPD Assessment Test (CAT) scores, inhaler adherence, inhaler technique, and patient satisfaction.

Baseline demographics and disease characteristics were similar between groups. At 3 months, the median CAT score was significantly lower in the telemedicine group (9, range 0–30) compared with the control group (18, range 0–34; P = .019), reflecting improved symptom control and quality of life. Inhaler technique was correct in 91.4% of telemedicine patients versus 65.7% of controls (P = .02). Inhaler adherence was higher in the telemedicine group (70.6% vs 55.9%), though not statistically significant (P > .05).

Patients in the telemedicine group also reported high satisfaction, minimal concern about remote examinations, and willingness to continue telemedicine in the future. Mortality and adverse event rates were similar between groups. No safety concerns emerged.

Limitations include the single-center design, small sample size, short 3-month follow-up, and the lack of CAT score data from interim control group visits. Additionally, only patients with severe COPD (GOLD 3–4) were included, which may limit generalizability to less severe populations.

“Telemedicine has improved the quality of life of advanced-stage COPD patients and their inhaler techniques,” Dogan and Kokturk concluded. “It may, therefore, be considered a promising alternative to traditional face-to-face follow-ups, although various technical infrastructures and legal regulations are necessary.”

Reference
Dogan ZS, Kokturk N. Evaluation of patients diagnosed with chronic obstructive pulmonary disease in terms of treatment compliance and quality of life after follow-up with telemedicine: a randomized controlled trial. BMC Pulm Med. 2025;25(1):408. doi:10.1186/s12890-025-03854-z